Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 760)
Posted On: 01/07/2022 2:43:50 PM
Post# of 153773
Posted By: ohm20
Re: kabonk #114144
Quote:
Trodelvy was approved for recurrent mTNBC (after failing two prior therapies), with a 529 patient randomized trial. It showed improvement in mPFS over a third line of chemo from 1.7 to 4.8 months.



The primary endpoint in that trial was median progression free survival and had a comparator arm of other drugs consisting of third line treatment. If you look at Erubilin's separate trial their mPFS was 4.1 months vs. the 4.8 for Trodelvy. A .7 month difference. In our study leronlimab's mPFS was 6.2 months a 1.4 month difference.

You make a big thing of different patient populations between the two trials but Trodelvy's trial excluded patients with brain metastasis. With the high rate of death in brain metastasis Gilead was using much healthier patients.













(18)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site